IL-4 regulates B-cell receptor signaling in CLL
نویسندگان
چکیده
منابع مشابه
TRAF3 regulates B cell survival and IL-6 receptor signaling
has been approved by the Examining Committee for the thesis requirement for the Doctor of Philosophy degree in Immunology at the May 2015 graduation. ii To my family and friends, thank you for the endless support iii ACKNOWLEDGEMENTS First and foremost, I would like to thank my mentor, Dr. Gail Bishop, for her mentorship and support for the past five years. Gail provided me with excellent guida...
متن کاملLeupaxin negatively regulates B cell receptor signaling.
The role of the paxillin superfamily of adaptor proteins in B cell antigen receptor (BCR) signaling has not been studied previously. We show here that leupaxin (LPXN), a member of this family, was tyrosine-phosphorylated and recruited to the plasma membrane of human BJAB lymphoma cells upon BCR stimulation and that it interacted with Lyn (a critical Src family tyrosine kinase in BCR signaling) ...
متن کاملHGAL localization to cell membrane regulates B-cell receptor signaling.
Human germinal center-associated lymphoma (HGAL) is specifically expressed only in germinal center (GC) B lymphocytes and GC-derived lymphomas. HGAL protein decreases lymphocyte motility by inhibiting the ability of myosin to translocate actin via direct interaction with F-actin and myosin II and by activating RhoA signaling via direct interactions with RhoA-specific guanine nucleotide exchange...
متن کاملB-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia.
Peripheral blood chronic lymphocytic leukemia (CLL) cells are quiescent but have active transcription and translation processes, suggesting that these lymphocytes are metabolically active. Based on this premise, the metabolic phenotype of CLL lymphocytes was investigated by evaluating the two intracellular ATP-generating pathways. Metabolic flux was assessed by measuring glycolysis as extracell...
متن کاملThe B-cell receptor signaling pathway as a therapeutic target in CLL.
Targeted therapy with imatinib and other selective tyrosine kinase inhibitors has transformed the treatment of chronic myeloid leukemia. Unlike chronic myeloid leukemia, chronic lymphocytic leukemia (CLL) lacks a common genetic aberration amenable to therapeutic targeting. However, our understanding of normal B-cell versus CLL biology points to differences in properties of B-cell receptor (BCR)...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2016
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood-2016-06-719872